About Phelba
A specialty company
built around
a perspective.
PHELBA Life Sciences engineers mechanism-informed bioactive systems
for brands building in metabolic, cognitive, inflammatory, and performance
health. We work in the space between molecule and market — and we keep
the portfolio small by design.
Where phytochemistry becomes product strategy.
The work that decides whether a product performs in the bottle, inthe body, and on the shelf — mechanism, matrix, dose architecture, format compatibility, regulatory framing — sits between the activeand the claim. That is where PHELBA works.
We curate ingredients, build systems around pathways, and translate
science into the kind of specifications that brand teams can defend in
market.
.png)
Samhita to Science.
Classical Ayurveda identified the bioactives we standardisetoday — Ashwagandha, Bacopa, Boswellia, Gymnema, Moringa— two millennia before HPLC existed. We treat that as a parallelresearch record, separated from modern pharmacology only bymethodology.
Our flagship monographs bridge classical Sanskrit references
with modern molecular validation — a practical advantage in
markets where heritage and evidence both matter.
A focused operating model.
Where our extracts ship.
PHELBA serves nutraceutical, functional food and beverage, sports-nutrition, personal-care, cosmeceutical, and pharmaceutical-grade buyers across the globe.
US
EU
UK
Japan
ASEAN
GCC
.png)
Global Standards
Harmonized Specifications
Insights
Perspectives from the formulation floor.
Long-form views on metabolic-health trends, botanical bioactive research, formulation strategy, and the evolving regulatory landscape — written with the rigor R&D and brand teams expect.
Mechanism Deep-Dives
The ChREBP/SREBP-1c angle on HCA — what the new MASLDliterature is telling us
Why EGCG is more than an antioxidant — a closer look at the COMT story
Withanolides and the HPA axis — a re-reading of the Ashwagandha clinical evidence
Bacosides, BDNF, and the cognitive aging conversation
Regulatory Updates
US DSHEA vs. EU Food Supplements — a quick comparison for botanical brands
Health Canada NHPID listings — what changed in 2026
Japan's Food with Function Claims — implications for botanical actives
EFSA's stance on EGCG and high-dose green-tea extracts
Market Notes
The GLP-1-adjacent supplement category — what is
defensible, what is not
Inside India's botanical-extract supply chain
How the green-coffee CGA market is segmenting in 2026
Functional beverages — where the metabolic-wellness category is heading
Formulation Strategy
Format-agnostic actives — when grade selection matters more than dose
Building a metabolic stack that works across capsules, sachets, and RTD
The synergy map — why ingredient combinations matter more than ingredients
Dose architecture — how to think about ratios in multi-active blends
Subscribe to PHELBA Insights.
One email a month. Mechanism, market, and regulatory perspectives for productdevelopers and brand teams.